Autologous peripheral blood stem cell (PBSC) transplants have been widely used for rapid hematologic recovery following myeloablative therapy for various malignant hematological disorders. A study enrolled 242 patients who consented to autologous PBSC transplant after myeloablative doses of chemotherapy between year 2003 and 2008 at the Edmonton Hematopoietic Stem Cell Lab in Cross Cancer Institute - Alberta Health Services. The Data is a data frame containing information about the patients' age, gender, as well as their clinical characteristics.
A data frame with 239 observations on the following 5 variables.
recovery rates for viable CD34+ cells
dummy variable indicating if a patient receives a chemotherapy on a one-day protocol(0) or on a 3-day protocol(1)
adjusted age variable.
age < 40 is set as the baseline age and other ages
are adjusted by subtracting by 40
Allan, D. and Keeney, M. and Howson-Jan, K. and Popma, J. and Weir, K. and Bhatia, M. and Sutherland, D. and Chin_yee, I. (2002) Number of Viable CD34+ Cells Reinfused Predicts Engraftment in Autologous Hematopoietic Stem Cell Transplantation. BONE MARROW TRANSPL, 20: 967-72
Yang, H. and Acker, J. and Cabuhat, M. and Letcher, B. and Larratt, L. and McGann, L. (2005) Association of Post_Thaw viable CD34+ Cells and CFU-GM with Time to Hematopoietic Engraftment. BONE MARROW TRANSPL, 35: 881-887
Zhang, P. and Qiu, Z. and Shi, C. (2016) simplexreg: An R Package for Regression Analysis of Proportional Data Using the Simplex Distribution. Journal of Statistical Software, 71: 1–21